Virbac : Feedback from the analysts’ meeting, a more difficult H2, although Virbac still boasts a number of attractive growth drivers
>Caution on H2 due to the effects of the COVID crisis - From the meeting, we retain the following points:1/ the CEO’s tone regarding forecasts. H2 2020 was described as “difficult”. Our interpretation of management’s comments is that Virbac should continue to outperform its market, the factors of operational uncertainty are not neutral (uncertain demand in India, Chile and the US, overstocking in Brazil, Mexico, Chile and India, a stoppage of more than two month...Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.